Eli Lilly and Company (LLY) Stock Analysis

Company Overview

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across the United States, Europe, China, Japan, and international markets, focusing heavily on cardiometabolic health products such as Basaglar and Humalog. The company operates within the Healthcare sector, specifically the Drug Manufacturers - General industry, positioning it as a key player in the production of essential medical treatments. Its operational scale is immense, evidenced by a market capitalization of $786.04B, annual revenue of $65.18B, and an employee count of 50000. These valuation and revenue figures indicate that the company holds a dominant position within the pharmaceutical landscape, commanding significant market share and resources relative to typical industry peers.

Financial Health

The company reported a trailing twelve-month revenue of $65.18B with net income of $20.64B and EBITDA of $31.69B. The substantial gap between revenue and net income reveals a highly efficient cost structure where operating expenses and taxes consume approximately 68.3% of total sales before reaching the bottom line. Free cash flow stands at $1.95B, which provides the organization with significant financial flexibility to fund research and development initiatives or manage capital expenditures without relying on external financing. Profitability is highlighted by a gross margin of 83.0%, an operating margin of 44.9%, and a profit margin of 31.7%, all of which indicate robust pricing power and efficient production processes. On the liability side, the company holds $7.27B in cash against $43.87B in debt, resulting in a debt-to-equity ratio of 165.31%, which suggests a leveraged balance sheet dependent on strong cash generation to service obligations. Liquidity is supported by a current ratio of 1.58, indicating that current assets are more than sufficient to cover short-term liabilities. Management effectiveness is further demonstrated by a return on equity of 101.2% and a return on assets of 19.4%, metrics that reveal exceptional capital efficiency in generating shareholder value.

Valuation Assessment

Valuation multiples show a trailing P/E ratio of 38.32 compared to a forward P/E of 20.86, implying that the market expects earnings to grow significantly in the future to justify the current high multiple. The price-to-book ratio is 29.62, indicating a substantial market premium over the company's book value, which reflects high investor expectations for future growth and intangible asset value. Alternative valuation metrics include a price-to-sales ratio of 12.06 and an EV/EBITDA of 25.91, suggesting the stock is priced based on anticipated revenue expansion rather than current asset base. Price action over the past year ranges from a 52-week low of $623.78 to a 52-week high of $1133.95. Without a specific current share price provided in the facts, the relative position cannot be calculated, but the wide range demonstrates significant price volatility over the last year. The stock exhibits a beta of 0.43, which means its price volatility is significantly lower than the broader market, offering a more stable investment profile compared to high-beta technology or consumer discretionary stocks.

Growth & Income

Revenue growth over the last year stands at 42.6%, while earnings growth is even more robust at 51.4%, indicating that earnings are growing faster than revenue due to margin expansion or cost efficiencies. The company pays a dividend yield of 0.7% with a payout ratio of 26.1%, a low payout ratio that is highly sustainable given the company's strong earnings growth and high profit margins. Because the payout ratio is low, the company retains a large portion of its earnings to reinvest into growth projects rather than distributing maximum dividends. Overall, the growth and income profile is defined by double-digit revenue expansion, accelerating earnings growth, and a conservative dividend policy that prioritizes capital allocation for long-term development.